Clinical Trial Update: Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating long-term safety and tolerability of octreotide acetate in patients with moderately severe or severe non-proliferative diabet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• OCTREOTIDE ACETATE (octreotide acetate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Retinopathy | Phase 3 | Status: TERMINATED